A possible role for the cholinergic anti-inflammatory pathway in increased mortality observed in critically ill patients receiving nicotine replacement therapy [11]

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2468-2469

  Kox, Matthijs ^a   Hoedemaekers, Astrid W ^a   Pickkers, Peter ^a   Van Der Hoeven, Johannes G ^a   Pompe, Jan C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; NEUROTRANSMITTER; NICOTINE; NICOTINIC AGENT;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CHOLINERGIC SYSTEM; CORONARY ARTERY CONSTRICTION; CRITICALLY ILL PATIENT; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; IMMUNOCOMPETENT CELL; INFECTION SENSITIVITY; INNATE IMMUNITY; LETTER; MORTALITY; NEUTROPHIL; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; VAGUS NERVE; WITHDRAWAL SYNDROME;

CRITICAL ILLNESS; HUMANS; NICOTINE; RECEPTORS, NICOTINIC; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; VAGUS NERVE;

EID: 34748864799     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000284498.88787.D7     Document Type: Letter

References (5)

1. van Westerloo DJ, Giebelen IA, Florquin S, et al: The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005; 191:2138-2148
2. Wang H, Yu M, Ochani M, et al: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421:384-388
3. Lee AH, Afessa B: The association of nicotine replacement therapy with mortality in a medical intensive care unit. Crit Care Med 2007; 35:1517-1521
4. Lewis SF, Piasecki TM, Fiore MC, et al: Transdermal nicotine replacement for hospitalized patients: A randomized clinical trial. Prev Med 1998; 27:296-303
5. Meine TJ, Patel MR, Washam JB, et al: Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976-978